← Leaderboards
Larry R Junck
University Of Michigan At Ann Arbor
$19,013
Attributed
$19,013
Total exposure
6
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$19,013 · 6
By mechanism
M01$19,013 · 6
Top collaborators
No co-investigators on record.
Most similar at University Of Michigan At Ann Arbor
Same institution · by research overlap
- Maria G Castro$22,126,725
- Daniel Dimaio$34,640,869
- Daniel A Lawrence$19,143,860
- Theodore S Lawrence$30,022,406
- Pedro R Lowenstein$13,187,884
Others in their field
Top investigators on “Human Subject”
- Sonia M Thomas · Research Triangle Institute$701,865,642
- Tracy L Nolen · Research Triangle Institute$474,487,152
- George R Seage · Abt Associates, Inc.$172,422,660
- Jay Arnold Tischfield · Rutgers, The State Univ Of N.J.$160,455,836
- Jeffrey P Krischer · University Of South Florida$155,493,283
- Charles A Coltman · Southwest Oncology Group$154,811,913
Research focus
Human SubjectClinical ResearchNeoplasm /Cancer ChemotherapyGlioblastoma MultiformeHuman Therapy EvaluationPlatelet Derived Growth FactorDrug Screening /EvaluationInhibitor /AntagonistBlood ChemistryBrain Electrical ActivityNeoplasm /Cancer Relapse /RecurrenceBrain MappingAstrocytomaPositron Emission TomographyBrain NeoplasmsProcarbazineBrain MetabolismClinical Trial Phase IClinical Trial Phase IiGliomaMotor CortexNeoplasm /Cancer SurgeryPatient Oriented ResearchCombination Chemotherapy
Grant awards (9)
Phase I/II Trial CPT-11&Temozolomide(Temodar)in Pts.w/Malignant Glioma UMCC 0048$14,741
M01 · FY2004 · RR
Phase I/II Trial of CCI-779 (NSC# 683864) in Patients w/ Malignant Glioma$3,558
M01 · FY2004 · RR
ZD1839 for Recurrent/ Progressive Malig Astrocytoma, Glioblastoma, &Meningioma$508
M01 · FY2004 · RR
SU101 VERSUS PROCARBAZINE FOR FIRST RELAPSE PATIENTS W/ GLIOBLASTOMA$0
M01 · FY2002 · RR
REGIONAL BRAIN ACTIVATION IN PATIENTS WITH BRAIN TUMORS$0
M01 · FY2002 · RR
Phase II study of SU101 for patients with anaplastic ast$0
M01 · FY2002 · RR
SU101 VERSUS PROCARBAZINE FOR FIRST RELAPSE PATIENTS W/ GLIOBLASTOMA$206
M01 · FY2000 · RR
REGIONAL BRAIN ACTIVATION IN PATIENTS WITH BRAIN TUMORS$0
M01 · FY2000 · RR
Phase II study of SU101 for patients with anaplastic ast$0
M01 · FY2000 · RR